Drug Profile
Etanercept biosimilar - Daewoong Pharmaceutical
Alternative Names: DWP 422Latest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Monoclonal antibodies; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in South Korea (Parenteral, Injection)
- 23 Jul 2012 Daewoong Pharmaceutical plans a phase I trial of DWP 422 in healthy volunteers in South Korea (NCT01635686)
- 23 May 2011 Etanercept biosimilar (DWP 422) licensed to Bi-nex